Transcripta Bio
Biotechnology company developing drugs through transcriptomic profiling and AI. · Health
How they use Nebius AI Cloud
Transcripta Bio develops drugs by comparing disease signatures with the effects of compounds on gene expression. Its Conductor AI platform uses transcriptomic data to identify compounds that could reverse disease signatures. Nebius described its atlas as containing over a billion gene responses.
Transcripta Bio won the Genomics and Multiomics category of the inaugural Nebius AI Discovery Awards in June 2025. The award provided Nebius AI Cloud GPU credits. VAST Data subsequently reported that Transcripta Bio was deploying the awarded resources for its research. Ronald van Loon’s interview post with team members also described Nebius support for scaling their transcriptomic research.
Sources
4 sourcesTranscripta Bio interview at the AI Discovery Awards
Published 1 Jul 2025 · LinkedIn · Web page
Ronald van Loon’s post featuring Transcripta Bio team members describes Nebius support for scaling the company’s transcriptomic research.
Open original sourceNebius inaugural AI Discovery Awards announcement
Published 23 Jun 2025 · Nebius · Web page
Nebius names Transcripta Bio as its Genomics and Multiomics award winner and describes its transcriptomic atlas. The announcement specifies Nebius AI Cloud GPU credits as the category prize.
Open original sourceNebius 2026 AI Discovery Awards announcement
Published 2 Jul 2026 · Nebius · Web page
Nebius’s 2026 awards announcement names Transcripta Bio among previous AI Discovery Awards winners.
Open original sourceCompany context
transcriptabio.comTranscripta Bio, operated by Transcripta Bio, Inc. in Palo Alto, develops drug candidates using transcriptomic profiling and artificial intelligence. Its Disease Signature Atlas maps gene expression in patient cells, its Drug-Gene Atlas measures how compounds change that expression, and Conductor AI identifies molecules that could reverse disease signatures. The company advances neurological and neuromuscular disease programs, including autism spectrum disorder, Huntington’s disease and muscular dystrophies. It also works with pharmaceutical companies, biotechnology companies, disease foundations and academic laboratories on drug discovery.
Recent updates
4 updatesTranscripta Bio and Mayo Clinic announce ALS research collaboration
Transcripta Bio announced a research collaboration and licensing agreement with Mayo Clinic focused on ALS. The partners plan to combine patient tissue, clinical expertise and transcriptomic drug discovery to map ALS biology and identify therapeutic targets and candidate treatments.
Transcripta BioTranscripta Bio and Synfini identify Huntington’s disease lead candidate
Transcripta Bio and Synfini announced that their research collaboration produced a lead candidate targeting MSH3, a gene implicated in Huntington’s disease progression. The companies said they reached the milestone within weeks by combining Transcripta’s target biology and compound signals with Synfini’s automated chemistry platform.
Transcripta BioTranscripta Bio expands scientific advisory board
Transcripta Bio announced additions to its scientific advisory board to guide its scientific and clinical strategy as its pipeline advances toward clinical development. The board brings expertise in human genetics, transcriptomic biology, drug development and neuromuscular trials.
Transcripta Bio